ROCKAWAY, NJ , Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus Medical Technologies (Cyrus), and Express Medical
ROCKAWAY, NJ , Jan. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference .
ROCKAWAY, N.J. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized,
ROCKAWAY, N.J. , Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United States . The site, which can be accessed through www.gammacore.com , allows
nVNS reduces symptoms of PTSD by 31% in sham-controlled study ROCKAWAY, N.J. , Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received Breakthrough Designation from the
Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, N.J. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) today published a letter from the company’s Board of Directors to shareholders.
Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke ROCKAWAY, N.J. , Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the
Data on 97-patient, randomized, sham-controlled study to be presented at medical congress later this year ROCKAWAY, N.J. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Conference Call to be Held at 4:30 PM Eastern Standard Time ROCKAWAY, N.J. , March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December